

# Contents

## Part I Animal Models for Central Nervous Tumors

<b>1 Modeling Gliomas Using PDGF-Expressing Retroviruses . . . . .</b>	<b>3</b>
Marcela Assanah, Kim A. Lopez, Jeffrey N. Bruce, and Peter Canoll	
<b>2 Modeling Brain Tumors Using Avian Retroviral Gene Transfer . . . . .</b>	<b>29</b>
Tod D. Holland and Eric C. Holland	
<b>3 Using Neurofibromatosis Type 1 Mouse Models to Understand Human Pediatric Low-Grade Gliomas . . . . .</b>	<b>45</b>
David H. Gutmann	
<b>4 Transgenic Mouse Models of CNS Tumors: Using Genetically Engineered Murine Models to Study the Role of p21-Ras in Glioblastoma Multiforme . . . . .</b>	<b>61</b>
Diana Munoz, Sameer Agnihotri, and Abhijit Guha	
<b>5 <i>Pten</i>-Deficient Mouse Models for High-Grade Astrocytomas . . . . .</b>	<b>77</b>
Chang-Hyuk Kwon	
<b>6 The <i>Nf1</i>-/+;<i>Trp53</i>-/+<i>cis</i> Mouse Model of Anaplastic Astrocytoma and Secondary Glioblastoma: Dissecting Genetic Susceptibility to Brain Cancer . . . . .</b>	<b>93</b>
Karlyne M. Reilly	
<b>7 Modeling Astrocytomas in a Family of Inducible Genetically Engineered Mice: Implications for Preclinical Cancer Drug Development. . . . .</b>	<b>119</b>
C. Ryan Miller, Natalie O. Karpnich, Qian Zhang, Elizabeth Bullitt, Serguei Kozlov, and Terry Van Dyke	

<b>8</b>	<b>Human Brain Tumor Cell and Tumor Tissue Transplantation Models. .</b>	<b>147</b>
	Tomoko Ozawa and C. David James	
<b>9</b>	<b>Transformed Human Brain Cells in Culture as a Model for Brain Tumors . . . . .</b>	<b>163</b>
	Russell O. Pieper	
<b>10</b>	<b>Rat Glioma Models for Preclinical Evaluation of Novel Therapeutic and Diagnostic Modalities . . . . .</b>	<b>181</b>
	Balveen Kaur and Rolf F. Barth	
<b>11</b>	<b>Neuro-oncogenesis Induced by Nitroso Compounds in Rodents and Strain-Specific Genetic Modifiers of Predisposition . . . . .</b>	<b>207</b>
	Bernd U. Koelsch and Andrea Kindler-Röhrborn	
<b>12</b>	<b>The Murine GL261 Glioma Experimental Model to Assess Novel Brain Tumor Treatments . . . . .</b>	<b>227</b>
	Elizabeth W. Newcomb and David Zagzag	
<b>13</b>	<b>Spontaneous Occurrence of Brain Tumors in Animals: Opportunities as Preclinical Model Systems . . . . .</b>	<b>243</b>
	Simon R. Platt	
<b>Part II Prognostic Factors and Biomarkers</b>		
<b>14</b>	<b>p53 Pathway Alterations in Brain Tumors . . . . .</b>	<b>283</b>
	Shaoman Yin and Erwin G. Van Meir	
<b>15</b>	<b>The PTEN/PI3 Kinase Pathway in Human Glioma. . . . .</b>	<b>315</b>
	David Stokoe and Frank B. Furnari	
<b>16</b>	<b>Value of 1p/19q and Other LOH Markers for Brain Tumor Diagnosis, Prognosis, and Therapy . . . . .</b>	<b>359</b>
	Jean-Louis Boulay and Adrian Merlo	
<b>17</b>	<b>Discovery of Genetic Markers for Brain Tumors by Comparative Genomic Hybridization . . . . .</b>	<b>373</b>
	Anjan Misra and Burt G. Feuerstein	
<b>18</b>	<b>Genomic Identification of Significant Targets in Brain Cancer . . . . .</b>	<b>395</b>
	Rameen Beroukhim, Gaddy Getz, and Ingo K. Mellinghoff	
<b>19</b>	<b>Oncomodulatory Role of the Human Cytomegalovirus in Glioblastoma . . . . .</b>	<b>415</b>
	Liliana Soroceanu and Charles S. Cobbs	

<b>20</b>	<b>Aberrant EGFR Signaling in Glioma</b> . . . . .	<b>441</b>
	YeoHyeon Hwang, Khatri Latha, Anupama Gururaj, Marta Rojas, and Oliver Bogler	
<b>21</b>	<b>Mechanisms of Brain Tumor Angiogenesis</b> . . . . .	<b>461</b>
	Bo Hu and Shi-Yuan Cheng	
<b>22</b>	<b>Vaso-occlusive Mechanisms that Initiate Hypoxia and Necrosis in Glioblastoma: The Role of Thrombosis and Tissue Factor</b> . . . . .	<b>507</b>
	Yuan Rong and Daniel J. Brat	
<b>23</b>	<b>Transcription Profiling of Brain Tumors: Tumor Biology and Treatment Stratification</b> . . . . .	<b>529</b>
	Erik P. Sulman, Marisol Guerrero, and Ken Aldape	
<b>24</b>	<b>Proteomic Profiling of Human Brain Tumors</b> . . . . .	<b>553</b>
	Rongcai Jiang, Jian Yi Li, Gregory N. Fuller, and Wei Zhang	
<b>25</b>	<b>Proteomic Discovery of Biomarkers in the Cerebrospinal Fluid of Brain Tumor Patients</b> . . . . .	<b>577</b>
	Fatima W. Khwaja and Erwin G. Van Meir	
<b>26</b>	<b>Epigenetic Profiling of Gliomas</b> . . . . .	<b>615</b>
	Raman P. Nagarajan and Joseph F. Costello	
<b>27</b>	<b>MicroRNAs in the Central Nervous System and Potential Roles of RNA Interference in Brain Tumors</b> . . . . .	<b>651</b>
	Benjamin Purow	
<b>28</b>	<b>Of <i>Escherichia coli</i> and Man: Understanding Glioma Resistance to Temozolomide Therapy</b> . . . . .	<b>679</b>
	Clark C. Chen, Kristopher T. Kahle, Kimberly Ng, Masayuki Nitta, and Alan D'Andrea	
<b>29</b>	<b>Brain Tumor Stem Cell Markers</b> . . . . .	<b>713</b>
	Jeremy N. Rich	
<b>Part III Therapeutic Targets and Targeting Approaches</b>		
<b>30</b>	<b>Clinical Agents for the Targeting of Brain Tumor Vasculature</b> . . . . .	<b>731</b>
	Elizabeth R. Gerstner and Tracy T. Batchelor	
<b>31</b>	<b>Bone Marrow-Derived Cells in GBM Neovascularization</b> . . . . .	<b>749</b>
	Gabriele Bergers	

<b>32</b>	<b>Vascular Targeting of Brain Tumors – Bridging the Gap with Phage Display</b> . . . . .	<b>775</b>
	Michael G. Ozawa, Fernanda I. Staquicini, Richard L. Sidman, Renata Pasqualini, and Wadih Arap	
<b>33</b>	<b>Impact of the Blood–Brain Barrier on Brain Tumor Imaging and Therapy</b> . . . . .	<b>789</b>
	James Provenzale	
<b>34</b>	<b>Targeting CXCR4 in Brain Tumors</b> . . . . .	<b>813</b>
	Hyunsuk Shim	
<b>35</b>	<b>Molecular Targeting of IL-13R<math>\alpha</math>2 and EphA2 Receptor in GBM</b> . . .	<b>847</b>
	Waldemar Debinski and Jill Wykosky	
<b>36</b>	<b>Molecular Targets for Antibody-Mediated Immunotherapy of Malignant Glioma</b> . . . . .	<b>865</b>
	Joanne E. Ayriss, Chien-Tsun Kuan, Susan T. Boulton, David A. Reardon, and Darell D. Bigner	
<b>37</b>	<b>Stat3 Oncogenic Signaling in Glioblastoma Multiforme</b> . . . . .	<b>899</b>
	Saikh Jaharul Haque and Pankaj Sharma	
<b>38</b>	<b>Inhibition of Ras Signaling for Brain Tumor Therapy</b> . . . . .	<b>919</b>
	Sameer Agnihotri, Diana Munoz, and Abhijit Guha	
<b>39</b>	<b>HGF/c-Met Signaling and Targeted Therapeutics in Brain Tumors</b> . . . . .	<b>933</b>
	Roger Abounader and John Laterra	
<b>40</b>	<b>Combinatorial Therapeutic Strategies for Blocking Kinase Pathways in Brain Tumors</b> . . . . .	<b>953</b>
	Paul H. Huang and Forest M. White	
<b>41</b>	<b>Targeting of TRAIL Apoptotic Pathways for Glioblastoma Therapies</b> . . . . .	<b>977</b>
	Anita C. Bellail, Patrick Mulligan, and Chunhai Hao	
<b>42</b>	<b>The NF-<math>\kappa</math>B Signaling Pathway in GBMs: Implications for Apoptotic and Inflammatory Responses and Exploitation for Therapy</b> . . . . .	<b>1011</b>
	Travis Laver, Susan Nozell, and Etty N. Benveniste	
<b>43</b>	<b>Targeting Endoplasmic Reticulum Stress for Malignant Glioma Therapy</b> . . . . .	<b>1037</b>
	Peter Pyrko, Axel H. Schönthal, and Thomas C. Chen	

<b>44</b>	<b>Brain Cancer Stem Cells as Targets of Novel Therapies</b> . . . . .	<b>1057</b>
	Jennifer M. Atkinson, Richard J. Gilbertson, and Jeremy N. Rich	
<b>45</b>	<b>The Use of Retinoids as Differentiation Agents Against Medulloblastoma</b> . . . . .	<b>1077</b>
	Matthew Wortham and Hai Yan	
<b>46</b>	<b>Herpes Simplex Virus 1 (HSV-1) for Glioblastoma Multiforme Therapy</b> . . . . .	<b>1105</b>
	Costas G. Hadjipanayis	
<b>47</b>	<b>The Development of Targeted Cancer Gene-Therapy Adenoviruses for High-Grade Glioma Treatment</b> . . . . .	<b>1137</b>
	Dawn E. Post and Erwin G. Van Meir	
<b>48</b>	<b>Harnessing T-Cell Immunity to Target Brain Tumors</b> . . . . .	<b>1165</b>
	Paul R. Walker, Robert M. Prins, Pierre-Yves Dietrich, and Linda M. Liau	
<b>49</b>	<b>Glioma Invasion: Mechanisms and Therapeutic Challenges</b> . . . . .	<b>1219</b>
	Mariano S. Viapiano and Sean E. Lawler	
	<b>Index</b> . . . . .	<b>1253</b>

CNS Cancer

Models, Markers, Prognostic Factors, Targets, and  
Therapeutic Approaches

Van Meir, E.G. (Ed.)

2009, XII, 1284 p. 160 illus., 64 illus. in color. With 2  
16-page color inserts., Hardcover

ISBN: 978-1-60327-552-1

A product of Humana Press